Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

1. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults

Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults. Lansdale: HAYES, Inc (...) .. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Adult; Anti-Obesity Agents; Humans; Liraglutide; Obesity; Weight Loss Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo

2015 Health Technology Assessment (HTA) Database.

2. Obese, overweight with risk factors: liraglutide (Saxenda)

Obese, overweight with risk factors: liraglutide (Saxenda) Obese, o Obese, ov verweight with risk factors: lir erweight with risk factors: liraglutide aglutide (Sax (Saxenda) enda) Evidence summary Published: 27 June 2017 nice.org.uk/guidance/es14 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2017. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory (...) status: Regulatory status: New medicine. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide (Saxenda) received a European marketing authorisation in March 2015 and was launched in the UK in January 2017. It is licensed as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of: 30 kg/m² or more (obese), or from 27 kg/m² to less than 30 kg/m² (overweight) in the presence of at least one weight

2017 National Institute for Health and Clinical Excellence - Advice

3. Liraglutide (Saxenda) and obesity: there are still no satisfactory weight loss drugs

Liraglutide (Saxenda) and obesity: there are still no satisfactory weight loss drugs Prescrire IN ENGLISH - Spotlight ''Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs'', 1 January 2016 {1} {1} {1} | | > > > Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs FEATURED REVIEW On average, daily liraglutide injections for one year help patients lose only a few kilograms compared with placebo, and weight is gradually regained after treatment discontinuation. Patients who are overweight or obese should not be exposed to the frequent gastrointestinal disorders and the risk of pancreatitis associated with long-term, high-dose liraglutide

2016 Prescrire

4. Randomised controlled trial: Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes

Randomised controlled trial: Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes Article Text Therapeutics/Prevention Randomised

2017 Evidence-Based Medicine (Requires free registration)

5. Saxenda (liraglutide) - for treatment of overweight

Saxenda (liraglutide) - for treatment of overweight Saxenda® (liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Saxenda® (liraglutide) Conclusion Saxenda is indicated for treatment of overweight in people with a BMI >30 or a BMI between 27 and 30 with at least one weight-related complication as an adjunct to a reduced-calorie diet and physical activity. Saxenda contains liraglutide, a long-acting glucagon-like peptide-1 (GLP-1 analogue (...) ) and is administered subcutaneously once daily. The dose is escalated over a period of four weeks to the daily maintenance dose of 3 mg liraglutide. Saxenda's exact mechanism of action in weight loss is not entirely clear. Overall, treatment with Saxenda produces a placebo-adjusted weight loss of 5.2%. The weight loss achieved was statistically significantly greater in women compared to men. Saxenda treatment gave a continuous decrease in weight during the first 40 weeks of treatment, after which the weight loss

2017 Danish Pharmacotherapy Reviews

6. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. (PubMed)

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 (...) diabetes.In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post

Full Text available with Trip Pro

2017 Lancet

7. Diabetes: avoid insulin degludec in combination with liraglutide

Diabetes: avoid insulin degludec in combination with liraglutide Prescrire IN ENGLISH - Spotlight ''Diabetes: avoid insulin degludec in combination with liraglutide'', 1 May 2017 {1} {1} {1} | | > > > Diabetes: avoid insulin degludec in combination with liraglutide Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Diabetes: avoid insulin degludec (...) in combination with liraglutide In patients with type 2 diabetes, the combination of insulin degludec and liraglutide in an injection pen has more disadvantages than advantages. In patients with type 2 diabetes, when metformin does not provide satisfactory glycaemic control, there is no evidence that the combination of liraglutide with an insulin is of any benefit in preventing clinical complications of diabetes. A fixed-dose combination in an injection pen of insulin degludec, a long-acting insulin

2017 Prescrire

8. Randomised controlled trial: Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants

Randomised controlled trial: Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants Article Text Therapeutics/Prevention Randomised controlled trial Subcutaneous

2015 Evidence-Based Medicine (Requires free registration)

9. Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria. (PubMed)

Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria. Cerebral malaria from Plasmodium falciparum infection is major cause of death in the tropics. The pathogenesis of the disease is complex and the contribution of reactive oxygen and nitrogen species (ROS/RNS) in the brain is incompletely understood. Insulinotropic glucagon-like peptide-1 (GLP-1) mimetics have potent neuroprotective effects in animal (...) models of neuropathology associated with ROS/RNS dysfunction. This study investigates the effect of the GLP-1 analogue, liraglutide against the clinical outcome of experimental cerebral malaria (ECM) and Plasmodium falciparum growth. Furthermore the role of oxidative stress on ECM pathogenesis is evaluated.ECM was induced in Plasmodium berghei ANKA-infected C57Bl/6j mice. Infected Balb/c (non-cerebral malaria) and uninfected C57Bl/6j mice were included as controls. Mice were treated twice-daily

Full Text available with Trip Pro

2016 Malaria journal

10. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. (PubMed)

Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss (...) by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes.Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling. Changes in SAT and VAT levels (determined by abdominal MRI), insulin sensitivity (according to the Matsuda index), and β-cell function (β-index) were assessed

Full Text available with Trip Pro

2017 Diabetes Care

11. Liraglutide for obesity or overweight in patients with associated co-morbidities

Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Liraglutide for obesity

2013 Health Technology Assessment (HTA) Database.

12. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. (PubMed)

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss.We did a randomised (...) , double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial. The study was done in eight countries involving 71 clinical sites. Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m2 or more. We randomly assigned participants (6:1) to each active treatment group (ie, semaglutide [0·05 mg, 0·1 mg, 0·2 mg, 0·3 mg, or 0·4 mg; initiated at 0·05 mg per day and incrementally escalated every 4 weeks] or liraglutide [3·0 mg

2018 Lancet

13. Liraglutide

Liraglutide Top results for liraglutide - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for liraglutide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

14. [Assessment of the LEADER study on liraglutide - rapid report]

[Assessment of the LEADER study on liraglutide - rapid report] Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09 [Assessment of the LEADER study on liraglutide - rapid report] Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09 [Assessment of the LEADER study on liraglutide - rapid report] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09. [Assessment of the LEADER study on liraglutide - rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 530. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2018 Health Technology Assessment (HTA) Database.

15. Assessment of the LEADER study on liraglutide - rapid report

Assessment of the LEADER study on liraglutide - rapid report 1 Translation of the executive summary of the rapid report Bewertung der Studie LEADER zu Liraglutid (Version 1.0; Status: 23 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. A17-09 Assessment of the LEADER study on liraglutide 1 Executive (...) summary of rapid report A17-09 Version 1.0 Assessment of the LEADER study on liraglutide 23 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Assessment of the LEADER study on liraglutide Commissioning agency: Federal Joint Committee Commission awarded on: 8 March 2017 Internal Commission No.: A17-09 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Type 2 diabetes: insulin degludec/liraglutide (Xultophy)

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) T T ype 2 diabetes: insulin degludec/lir ype 2 diabetes: insulin degludec/liraglutide aglutide (Xultoph (Xultophy) y) Evidence summary Published: 3 July 2015 nice.org.uk/guidance/esnm60 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) - to-date information. Summary In people who are insulin-naïve, insulin degludec/liraglutide (Xultophy) was non-inferior to insulin degludec alone and superior to liraglutide alone for reductions in HbA1c (with a difference of 0.64% compared with liraglutide). In people previously treated with basal insulin, insulin degludec/ liraglutide was superior to insulin degludec alone for reducing HbA1c with a difference of 1.1%. The safety profile and long-term safety concerns of insulin degludec/liraglutide

2015 National Institute for Health and Clinical Excellence - Advice

17. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. (PubMed)

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had (...) a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions

Full Text available with Trip Pro

2015 NEJM

18. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. (PubMed)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. To evaluate whether liraglutide or roflumilast significantly affects body weight when compared to metformin in obese women with PCOS.A 12-week prospective randomized open-label study was conducted with 45 obese women with PCOS diagnosed by the ASRM-ESHRE Rotterdam criteria. They were randomized to metformin (MET (...) ) 1000 mg BID or liraglutide (LIRA) 1.2 mg QD s.c. or roflumilast (ROF) 500 mcg QD. The primary outcome was change in measures of obesity.Forty-one patients (aged 30.7 ± 7.9 years, BMI 38.6 ± 6.0 kg/m2, mean ± SD) completed the study. Subjects treated with LIRA lost on average 3.1 ± 3.5 kg (p = 0.006), on ROF 2.1 ± 2.0 kg (p = 0.002) vs. 0.2 ± 1.83 kg in MET group. BMI decreased for 1.1 ± 1.26 kg/m2 in LIRA (p = 0.006), for 0.8 ± 0.99 kg/m2 in ROF (p = 0.001) vs. 0.1 ± 0.67 kg/m2 in MET. LIRA

Full Text available with Trip Pro

2015 Journal of ovarian research

19. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. (PubMed)

Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. As an adjunct to a reduced-calorie diet and increased physical activity, treatment with liraglutide 3.0 mg for weight management provides a statistically significant and clinically meaningful weight loss of 5.7%-8.0% compared to 1.6%-2.6% with placebo. The objective of this post hoc analysis was to quantify the relative contribution of weight loss to the treatment effects of liraglutide 3.0 mg on key (...) efficacy endpoints.The analysis utilized data from 4725 participants across three randomized, placebo-controlled, double-blind trials that evaluated the efficacy and safety of liraglutide 3.0 mg versus placebo, as an adjunct to a reduced-calorie diet and increased physical activity (ClinicalTrials.gov identifiers: NCT01272219, NCT01272232 and NCT01557166). The duration of two of the trials was 56 weeks; one trial was of 32 weeks' duration. A mediation analysis was performed, which ranked the relative

2016 Current medical research and opinion

20. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (PubMed)

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal (...) myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjustments for multiplicity were performed for the prespecified exploratory outcomes.A total of 9340 patients underwent randomization. The median follow-up was 3.8 years. The primary outcome occurred in significantly fewer patients in the liraglutide

Full Text available with Trip Pro

2016 NEJM